Achieving therapeutic targets in renal anaemia: considering cost-efficacy

References

• Kimmel PL, Greer JW, Milam RA, Thamer M. Trends in erythropoietin therapy in the U.S. dialysis population: 1995 to 1998. Semin Nephrol 2000;20: 335–44
   Google Scholar
• Obrador GT, Pereira BJ. Anaemia of chronic kidney disease: an under-recognized and under-treated problem. Nephrol Dial Transplant 2002;17(Suppl 11):44–6
   PubMed Web of Science ®Google Scholar
• Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant 1996;11:1277–85
   PubMed Web of Science ®Google Scholar
• Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996;28:53–61
   PubMed Web of Science ®Google Scholar
• Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990;300:573–8
   PubMed Web of Science ®Google Scholar
• Bárány P, Pettersson E, Konarski-Svensson JK. Long-term effects on quality of life in haemodialysis patients of correction of anaemia with erythropoietin. Nephrol Dial Transplant 1993;8:426–32
   Google Scholar
• Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther 2003;25:1786–805
   PubMed Web of Science ®Google Scholar
• Cannella G, La Canna G, Sandrini M, et al. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991;6:31–7
   PubMed Web of Science ®Google Scholar
• Möcks J. Cardiovascular mortality in haemodialysis patients treated with epoetin beta – a retrospective study. Nephron 2000;86:455–62
   PubMed Web of Science ®Google Scholar
• Silverberg D. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant 2003;18\(Suppl 2):ii7–ii12
   Google Scholar
• Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguch Y, Sakai O. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Nephron 1997;77:176–85
   PubMed Web of Science ®Google Scholar
• Portolés J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997;29:541–8
   Google Scholar
• Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18\(Suppl 2):ii2–ii6
   Google Scholar
• Fink J, Blahut SA, Reddy M, Light P. Use of erythropoietin before the initiation of dialysis and its impact on mortality. Am J Kidney Dis 2001;37:348–55
   PubMed Web of Science ®Google Scholar
• Xue JL, St Peter WL, Ebben JP, Everson SE, Collins AJ. Anemia treatment in the pre-ESRD period and associated mortality in elderly patients. Am J Kidney Dis 2002;40:1153–61
   PubMed Web of Science ®Google Scholar
• NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease, update 2000. Am J Kidney Dis 2001;37(Suppl 1):S182–S238
   PubMed Web of Science ®Google Scholar
• European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999;14\(Suppl 5):1–50
   Google Scholar
• United States Renal Data System 2003, Annual Data Report 2003 (http://www.usrds.org/2003/pdf/11_econ_03.pdf)
   Google Scholar
• Brophy DF, Ripley EB, Holdford DA. Pharmacoeconomic considerations in the health system management of anaemia in patients with chronic kidney disease and end stage renal disease. Expert Opin Pharmacother 2003;4:1461–9
   Google Scholar
• Morreale A, Plowman B, DeLattre M, Boggie D, Schaefer M. Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Curr Med Res Opin 2004;20:381–95
   Google Scholar
• DeVita MV, Frumkin D, Mittal S, Kamran A, Fishbane S, Michelis MF. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients. Clin Nephrol 2003;60:335–40
   PubMed Web of Science ®Google Scholar
• Coronel F, Herrero JA, Montenegro J, et al. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis. J Nephrol 2003;16:697–702
   PubMed Web of Science ®Google Scholar
• Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:439–46
   Google Scholar
• Kaufman JS. Subcutaneous erythropoietin therapy: efficacy and economic implications. Am J Kidney Dis 1998;32 (Suppl 4):S147–S151
   PubMedGoogle Scholar
• Pisoni RL. Erythropoietin therapy in Europe: results from the DOPPS. Contrib Nephrol 2002;137:396–402
   PubMed Web of Science ®Google Scholar
• Parker KP, Mitch WE, Stivelman JC, Macon EJ, Bailey JL, Sands JM. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol 1997;8:288–93
   PubMed Web of Science ®Google Scholar
• Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. New Engl J Med 1998;339:578–83
   PubMed Web of Science ®Google Scholar
• Hynes DM, Stroupe KT, Greer JW, et al. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med 2002;112:169–75
   PubMed Web of Science ®Google Scholar
• Fraticelli M, D’Amico M, Conte F. Intravenous versus subcutaneous EPO: is the cost benefit acceptable? Am J Kidney Dis 2003;41:1122–7
   PubMed Web of Science ®Google Scholar
• Kleophas W, Kult J, Kreusser W, et al. Tolerability and efficacy of multidose epoetin beta (Reco-Pen®) for subcutaneous administration in patients with anemia due to renal failure. Kidney Blood Press Res 2003;26:192–8
   PubMed Web of Science ®Google Scholar
• Navarro JF, Teruel JL, Marcén R, Ortuño J. Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route. Scand J Urol Nephrol 1995;29:11–4
   PubMed Web of Science ®Google Scholar
• NeoRecormon® summary of product characteristics. Roche Registration Ltd, UK. Issued March 2003
   Google Scholar
• Aranesp® summary of product characteristics. Amgen Inc, July 2001
   Google Scholar
• Aljama P, Bommer J, Canaud B, et al. Practical guidelines for the use of NESP in treating renal anaemia. Nephrol Dial Transplant 2001;16(Suppl 3):22–8
   PubMed Web of Science ®Google Scholar
• Vanrenterghem Y, Barany P, Mann JF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int 2002;62:2167–75
   PubMed Web of Science ®Google Scholar
• Eprex® summary of product characteristics. Janssen Cilag Ltd, UK. Issued April 2003
   Google Scholar
• Gallar Ruiz P, Balcke P, Montenegro Martinez J, Harris K. Tolerability of the epoetin-beta multidose formulation (Reco-Pen®) in patients with renal anaemia. Clin Drug Invest 2000;20:151–8
   Web of Science ®Google Scholar
• Raftery MJ, Auinger M, Hertlová M. Safety and tolerability of a multidose formulation of epoetin beta in dialysis patients. Clin Nephrol 2000;54:240–5
   Google Scholar
• Veys N, Dhondt A, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol 1998;49:41–4
   Google Scholar
• Veys N, Vanholder R, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. Am J Nephrol 1992;12:68–72
   Google Scholar
• Macdougall IC, Matcham J, Gray SJ. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2003;18:576–81
   Google Scholar
• De Cock E, Van Bellinghen L, Standaert B. Assessing provider time for anaemia management of dialysis patients using time and motion methods: a multi-centre observational study in Europe. Value Health 2002;5:581
   Web of Science ®Google Scholar
• Frifelt JJ, Tvedegaard E, Bruun K, et al. Efficacy of recombinant human erythropoietin administered subcutaneously to CAPD patients once weekly. Perit Dial Int 1996;16:594–8
   PubMed Web of Science ®Google Scholar
• Weiss LG, Clyne N, Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin b: results from a randomized controlled multicentre trial. Nephrol Dial Transplant 2000;15:2014–9
   Google Scholar
• Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL. Once-weekly compared with three-times-weekly sub-cutaneous epoetin b: results from a randomized, multicenter therapeutic-equivalence study. Am J Kidney Dis 2002;40:119–25
   Google Scholar
• Grzeszczak W, Sulowicz W, Rutkowski B, et al. The efficacy and safety of once weekly and once fortnightly subcutaneous epoetin b in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant [submitted]
   Google Scholar
• Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 2002;24:1871–86
   PubMed Web of Science ®Google Scholar
• Richter A, Anton SF, Koch P, Dennett SL. The impact of reducing dose frequency on health outcomes. Clin Ther 2003;25:2307–35
   PubMed Web of Science ®Google Scholar
• Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 2002;22:160S–165S
   Google Scholar
• Locatelli F, Olivares J, Walker R, et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741–7
   PubMed Web of Science ®Google Scholar
• Deray G. Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant 2003;18:2455–6
   PubMed Web of Science ®Google Scholar